Q3 Results February 09 Live: BSE, Zydus Lifesciences, Aurobindo Pharma, Linde India, Axiscades Tech, GlaxoSmithKline Pharma, Navin Fluorine Intl, Cholamandalam Financial Holdings, Ramco Cements, Amber Enterprises, Trident, Graphite India, Bata announces Q3 results

Third Quarter Results Live: Pearl Global Industries Limited announces their third quarter performance

Shares of Pearl Global Industries Limited were trading at ₹1,778.70 on the NSE today, down ₹56.10 or 3.06 percent after the results.

Consolidated financial highlights for 9MFY26: Revenue at ₹3,711 crore, up 13.2 percent year-on-year, driven by high sales growth of value-added products in Vietnam and Indonesia

Adjusted EBITDA (excl. ESOP expenses) at ₹333 crore, grew 14.0 percent YoY, EBITDA margin at ~9.0 percent

Adjustment EBITDA margin excluding mutual tariff impact of ~₹31 crore and incremental cost of new business of ~₹11 crore stands at ~10.1 percent

PAT grew to ₹189 crore, up 14.0 percent year-on-year

Consolidated Financial Highlights for Q3FY26: Revenue at ₹1,170 crore, growing 14.4 percent YoY

Adjustment EBITDA (excl. ESOP costs) was ₹97 crore, up 4.4 percent YoY, with a margin of 8.3 percent

Adjustment EBITDA margin excluding mutual tariff impact and incremental cost of new business of ~₹9 crore is ~9.1 percent

PAT grew to ₹52 crore, up 6.8 percent year-on-year

Standalone financial highlights for 9MFY26: Revenue stands at ₹777 crore

Adjustment EBITDA (excl. ESOP costs) at ₹43 crore, grew 63.7 percent YoY, EBITDA margin at 5.5 percent, improved 220 basis points YoY, mainly due to cost restructuring

Adjustment EBITDA margin excluding cross tariff cost of ₹~14 crore is ~7.3 percent

PAT at ₹55 crore, compared to ₹32 crore in 9M FY25

Standalone financial highlights for Q3FY26: Revenue at ₹246 crore

Adjustment EBITDA at ₹13 crore, EBITDA margin at 5.1 percent, improved by 140 bps YoY

Adjustment EBITDA margin excluding cross tariff cost of ₹~5 crore is ~7.2 percent

PAT stands at ₹14 crore, compared to ₹4 crore in Q3 FY25

Q3 results live: Procter & Gamble Health Ltd. (PGHL) has announced their results

The shares of Procter & Gamble Health Ltd. (PGHL) were trading at ₹5,249.50, up ₹59.50 or 1.15 percent.

Procter & Gamble Health Ltd. (PGHL) today announced its financial results for the third quarter ended December 31, 2025. The company posted revenues of ₹368 crores, up 21 percent year-on-year, driven by strong brand fundamentals and positive consumer response to new innovations. Profit after tax (PAT) stood at ₹78 crores this quarter.

Q3 Results Live: Filatex India Limited announced results on Saturday.

Shares of Filatex India Limited were trading at ₹51.77 on the NSE today morning, up ₹3.62 or 7.52 percent.

Standalone revenue from operations stood at ₹1,049.70 crore for Q3FY26 and ₹3,175.03 crore for 9MFY26. EBITDA was reported at ₹93.58 crore with a margin of 8.91 per cent for Q3FY26 and ₹260.27 crore for 9MFY26, up 43.02 per cent YoY. PAT stood at ₹55.34 crore with a margin of 5.27 per cent for Q3FY26 and ₹143.65 crore for 9MFY26, up 54.15 per cent YoY.

Filatex India Limited is an integrated, ESG-oriented polyester filament yarn manufacturer pioneering India’s ecosystem of next-generation circular materials and exporting to over 40 countries.

During the quarter, Filatex advanced its Ecosis platform for circular textile-to-textile recycling, advanced sustainability and renewable energy initiatives, and continued its commitment to Decathlon as a key global customer.